AYTU BioPharma, Inc.
AYTUAytu BioPharma is a specialty pharmaceutical company focused on commercializing innovative prescription therapeutics for complex central nervous system (CNS) diseases and pediatric conditions.
Table of contents
Earnings
Next report
Sep 22, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Aytu BioPharma is a specialty pharmaceutical company focused on commercializing innovative prescription therapeutics for complex central nervous system (CNS) diseases and pediatric conditions. The company leverages a commercial infrastructure and a proprietary patient access platform to market branded treatments for major depressive disorder, ADHD, and allergic conditions. Its core strategy involves in-licensing and acquiring revenue-generating products while optimizing manufacturing through third-party partnerships.
Aytu maintains a niche position by offering the first and only FDA-approved orally disintegrating tablet formulations for ADHD and a novel first-in-class antidepressant without sexual dysfunction warnings.
Questions, answered.
- What is AYTU BioPharma, Inc.'s market cap?
- AYTU BioPharma, Inc. (AYTU) has a market capitalization of $23.6M and trades on NASDAQ.
- Who are AYTU BioPharma, Inc.'s competitors?
- AYTU BioPharma, Inc.'s key competitors include Pfizer Inc., Teva Pharmaceutical Industries Limited, Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does AYTU BioPharma, Inc. partner with?
- AYTU BioPharma, Inc.'s notable partners include Fabre-Kramer Holdings, Inc., Tris Pharma, Inc., Merck & Cie, and others.
- What subsidiaries does AYTU BioPharma, Inc. have?
- AYTU BioPharma, Inc.'s subsidiaries include Neos Therapeutics.
- Where is AYTU BioPharma, Inc. headquartered?
- AYTU BioPharma, Inc. is headquartered in United States of America and employs approximately 150 people. It has been publicly traded since 2008.